Clinical Trial

Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated September 8, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an open-label clinical trial aimed at evaluating the safety and efficacy of the combination treatment of nelmastobart with capecitabine in patients diagnosed with metastatic or recurrent colorectal cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-06.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-09-01
Trial Details
NCT Number NCT05990543
Lead Sponsor Korea University Anam Hospital
Conditions Recurrent or Metastatic Colorectal Cancer
Enrollment 59 participants
Start Date 2024-01-29
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-08